The antitumor effects of IFN-α are abrogated in a STAT1-deficient mouse

Journal of Clinical Investigation

Volumn 112, Issue 2, 2003, Pages 170-180

  Lesinski, Gregory B ^a   Anghelina, Mirela ^a   Zimmerer, Jason ^a   Bakalakos, Timothy ^a   Badgwell, Brian ^a   Parihar, Robin ^a   Hu, Yan ^a   Becknell, Brian ^a   Abood, Gerard ^a   Chaudhury, Abhik Ray ^a   Magro, Cynthia ^a   Durbin, Joan ^a,b   Carson III, William E ^a,c  

^a OHIO STATE UNIVERSITY   (United States)

^b NATIONWIDE CHILDREN S HOSPITAL   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; STAT PROTEIN; STAT1 PROTEIN; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; DNA BINDING PROTEIN; STAT1 PROTEIN, MOUSE; TRANSACTIVATOR PROTEIN;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL SURVIVAL; CONTROLLED STUDY; GENE CONTROL; GENE TRANSFER; IMMUNOSTIMULATION; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN FAMILY; ANIMAL; C57BL MOUSE; CELL CULTURE; CELL DIVISION; CELL LINE; CYTOLOGY; DOSE RESPONSE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENETICS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MOUSE MUTANT; PHYSIOLOGY; RETROVIRUS; SIGNAL TRANSDUCTION; SPLEEN; TIME; TRANSGENIC MOUSE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL DIVISION; CELL LINE; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENE TRANSFER TECHNIQUES; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; INTERFERON-ALPHA; KILLER CELLS, NATURAL; MICE; MICE, INBRED C57BL; MICE, SCID; MICE, TRANSGENIC; RETROVIRIDAE; SIGNAL TRANSDUCTION; SPLEEN; STAT1 TRANSCRIPTION FACTOR; TIME FACTORS; TRANS-ACTIVATORS; TUMOR CELLS, CULTURED;

EID: 85047689957     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI16603     Document Type: Article

References (55)

1. Kirkwood, J.M., Ibrahim, J.G., Sondak, V.K., Ernstoff, M.S., and Ross, M. 2002. Interferon alfa-2a for melanoma metastases. Lancet. 359:978-979.
2. Belardelli, F., Ferrantini, M., Proietti, E., and Kirkwood, J.M. 2002. Interferon-alpha in tumor immunity and immunotherapy. Cytokine Growth Factor Rev. 13:119-134.
3. Kirkwood, J.M., et al. 2000. High- and low-dose inter Feron alfa-2b in high-risk melanoma: First analysis of intergroup trial E1690/S9111/C9190. J. Clin. Oncol. 18:2444-2458.
4. Agarwala, S.S., and Kirkwood, J.M. 1995. Potential uses of interferon alpha 2 as adjuvant therapy in cancer. Ann. Surg. Oncol. 2:365-371.
5. Biron, C.A. 2001. Interferons alpha and beta as immune regulators-a new look. Immunity. 14:661-664.
6. + cells From patients with chronic myeloid leukemia and interferon-α upregulates this expression. Haematologica. 85:139-146.
7. von Stamm, U., et al. 1993. Effects of systemic interferon-alpha (IFN-alpha) on the antigenic phenotype of melanoma metastases. EORTC Melanoma Group Cooperative Study No. 18852. Melanoma Res. 3:173-180.
8. Ezekowitz, R.A., Mulliken, J.B., and Folkman, J. 1992. Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N. Engl. J. Med. 326:1456-1463.
9. Slaton, J.W., Perrotte, P., Inoue, K., Dinney, C.P., and Fidler, I.J. 1999. Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin. Cancer Res. 5:2726-2734.
10. Haque, S.J., and Williams, B.R. 1998. Signal transduction in the interferon system. Semin. Oncol. 25:14-22.
11. Leonard, W.J., and O'Shea, J.J. 1998. Jaks and STATs: biological implications. Annu. Rev. Immunol. 16:293-322.
12. Darnell, J.E., Jr., Kerr, I.M., and Stark, G.R. 1994. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science. 264:1415-1421.
13. Levy, D.E., Kessler, D.S., Pine, R., Reich, N., and Darnell, J.E., Jr. 1988. Interferon-induced nuclear factors that bind a shared promoter element correlate with positive and negative transcriptional control. Genes Dev. 2:383-393.
14. Vujanovic, N.L., Basse, P., Herberman, R.B., and Whiteside, T.L. 1996. Antitumor functions of natural killer cells and control of metastases. Methods. 9:394-408.
15. Lee, C.K., et al. 2000. Distinct requirements for IFNs and STAT1 in NK cell function. J. Immunol. 165:3071-3577.
16. Carson, W.E., et al. 1999. A fatal cytokine-induced systemic inflammatory response reveals a critical role for NK cells. J. Immunol. 162:4943-4951.
17. Carson, W.E., and Walker, M.J. 2000. Animal models of malignant melanoma. In Tumor models in cancer. B.A. Teicher, editor. Humana Press. Tolowa, New Jersey, USA. 471-492.
18. Berkelhammer, J., Oxenhandler, R.W., Hook, R.R., Jr., and Hennessy, J.M. 1982. Development of a new melanoma model in C57BL/6 mice. Cancer Res. 42:3157-3163.
19. Durbin, J.E., Hackenmiller, R., Simon, M.C., and Levy, D.E. 1996. Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease. Cell. 84:443-450.
20. Bosma, G.C., Custer, R.P., and Bosma, M.J. 1983. A severe combined immunodeficiency mutation in the mouse. Nature. 301:527-530.
21. Sadowski, H.B., Shuai, K., Darnell, J.E., Jr., and Gilman, M.Z. 1993. A common nuclear signal transduction pathway activated by growth factor and cytokine receptors. Science. 261:1739-1744.
22. Ruff-Jamison, S., et al. 1994. Epidermal growth factor and lipopolysaccharide activate Stat3 transcription factor in mouse liver J. Biol. Chem. 269:21933-21935.
23. Cherry, S.R., Biniszkiewicz, D., van Parijs, L., Baltimore, D., and Jaenisch, R. 2000. Retroviral expression in embryonic stem cells and hematopoietic stem cells. Mol. Cell. Biol. 20:7419-7426.
24. Walter, M.J., Look, D.C., Tidwell, R.M., Roswit, W.T., and Holtzman, M.J. 1997. Targeted inhibition of interferon-gamma-dependent intercellular adhesion molecule-1 (1CAM-1) expression using dominant-negative Stat1. J. Biol. Chem. 272:28082-28589.
25. Pear, W.S., Nolan, G.P., Scott, M.L., and Baltimore, D. 1993. Production of high-titer helper-free retroviruses by transient transfection. Proc. Natl. Acad. Sci. U. S. A. 90:8392-8396.
26. Fleisher, T.A., et al. 1999. Detection of intracellular phosphorylated STAT-1 by flow cytometry. Clin. Immunol. 90:425-430.
27. Hobart, M., Ramassar, V., Goes, N., Urmson, J., and Halloran, P.F. 1997 IFN-regulatory factor-1 plays a central role in the regulation of the expression of class I and II MHC genes in vivo J. Immunol. 158:4260-4269.
28. Yang, C.H., et al. 2000. IFNalpha/beta promotes cell survival by activating NF-kappa B. Proc. Natl. Acad Sci. U. S. A. 97:13631-13636.
29. Suzuki, K., et al. 1999. Activation of target-tissue immune-recognition molecules by double-stranded polynucleotides. Proc. Natl. Acad. Sci U. S. A. 96:2285-2290.
30. Bluyssen, H.A., et al. 1994. Structure, chromosome localization, and regulation of expression of the interferon-regulated mouse Ifi54/Ifi56 gene family. Genomics. 24:137-148.
31. Hassouna, N., Michot, B., and Bachellerie, J.P. 1984. The complete nucleotide sequence of mouse 28S rRNA gene. Implications for the process of size increase of the large subunit rRNA in higher eukaryotes. Nucleic Acids Res. 12:3563-3583.
32. Fleischmann, C.M., Stanton, G.J., and Fleischmann, W.R., Jr. 1996. Enhanced in vivo sensitivity of in vitro interferon-treated B16 melanoma cells to CD8 cells and activated macrophages. J. Interferon Cytokine Res. 16:805-812.
33. Shrayer, D.P., Bogaars, H., Wolf, S.F., Hearing, V.J., and Wanebo, H.J. 1998. A new mouse model of experimental melanoma for vaccine and lymphokine therapy. Int. J. Oncol. 13:361-374.
34. Fehniger, T.A., Carson, W.E., Mrozek, E., and Caligiuri, M.A. 1997. Stem cell factor enhances interleukin-2-mediated expansion of murine natural killer cells in vivo. Blood. 90:3647-3653.
35. Tessitore, A., et al. 1998. Two gamma-interferon-activation sites (GAS) on the promoter of the human intercellular adhesion molecule (ICAM-1) gene are required for induction of transcription by IFN-gamma. Eur. J. Biochem. 258:968-975.
36. Kurosawa, S., et al. 1995. Early-appearing tumour-infiltrating natural killer cells play a crucial role in the generation of anti-tumour T lymphocytes. Immunology. 85:338-346.
37. Liao, S.K., Kwong, P.C., Khosravi, M., and Dent, P.B. 1982. Enhanced expression of melanoma-associated antigens and beta 2-microglobulin on cultured human melanoma cells by interferon. J. Natl. Cancer Inst. 68:19-25.
38. Navarro, S., Colamonici, O.R., and Llombart-Bosch, A. 1996. Immunohistochemical detection of the type I interferon receptor in human fetal, adult, and neoplastic tissues. Mod. Pathol. 9:150-156.
39. Carson, W.E. 1998. Interferon-alpha-induced activation of signal transducer and activator of transcription proteins in malignant melanoma. Clin. Cancer Res. 4:2219-2228.
40. Pansky, A., et al. 2000. Defective Jak-STAT signal transduction pathway in melanoma cells resistant to growth inhibition by interteron-alpha. Int. J. Cancer. 85:720-725.
41. Wong, L.H., Hatzinisiriou, I., Devenish, R.J., and Ralph, S.J. 1998. IFN-gamma priming up-regulates IFN-stimulated gene factor 3 (ISGF3) components, augmenting responsiveness of IFN-resistant melanoma cells to type I IFNs. J. Immunol. 160:5475-S484.
42. Kaplan, D.H., et al. 1998. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc. Natl. Acad. Sci. U. S. A. 95:7556-7561.
43. Huang, S., Bucana, C.D., Van Arsdall, M., and Fidler, I.J. 2002. Stat1 negatively regulates angiogenesis, tumorigenicity and metastasis of tumor cells. Oncogene 21:2504-2512.
44. Gil, M.P., et al. 2001. Biologic consequences of Stat1-independent IFN-signaling. Proc Natl. Acad. Sci. U. S. A. 98:6680-6685.
45. Wong, A.H., et al. 1997. Physical association between STAT1 and the interferon-inducible protein kinase PKR and implications for interferon and double-stranded RNA signaling pathways. EMBO J. 16:1291-1304.
46. Ramana, C.V., et al. 2001. Stat1-independent regulation of gene expression in response to IFN-gamma. Proc. Natl. Acad. Sci. U. S. A. 98:6674-6679.
47. Uddin, S., et al. 1999. Activation of the p38 mitogen-activated protein kinase by type I interferons. J. Biol. Chem. 274:30127-30131.
48. Deb, A., Haque, S.J., Mogensen, T., Silverman, R.H., and Williams, B.R. 2001. RNA-dependent protein kinase PKR is required for activation of NF-kappa B by IFN-gamma in a STAT1-independent pathway. J. Immunol. 166:6170-6180.
49. Moretti, S., et al. 2001. Serum imbalance of cytokines in melanoma patients. Melanoma Res 11:395-399.
50. Lauerova, L., et al. 2002. Malignant melanoma associates with Th1/Th2 imbalance that coincides with disease progression and immunotherapy response. Neoplasma. 49:159-166.
51. Ueda, M., et al. 1986. Time-dependent suppression of melanoma metastases and natural killer cell activation by interferon. Arch. Dermatol. Res. 278:329-334.
52. Markovic, S.N., and Murasko, D.M. 1991. Role of natural killer and T-cells in interferon induced inhibition of spontaneous metastases of the B16F10L murine melanoma. Cancer Res. 51:1124-1128.
53. Hersey, P., et al. 1986. Immunological effects of recombinant interferon alfa-2a in patients with disseminated melanoma. Cancer. 57:1666-1674.
54. Golub, S.H., Dorey, F., Hara, D., Morton, D.L., and Burk, M.W. 1982. Systemic administration of human leukocyte interferon to melanoma patients. I. Effects on natural killer function and cell population. J. Natl. Cancer Inst. 68:703-710.
55. Seo, N., Tokura, Y., Furukawa, F., and Takigawa, M. 1998. Down-regulation of tumoricidal NK and NK T cell activities by MHC Kb molecules expressed on Th2-type gammadelra T and alphabeta T cells coinfiltrating in early B16 melanoma lesions. J. Immunol. 161:4138-4145.